CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 86 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,572,622 | +305.8% | 52,879 | +145.9% | 0.00% | – |
| Q2 2023 | $387,574 | +17.1% | 21,508 | +4.4% | 0.00% | – |
| Q1 2023 | $330,932 | -12.2% | 20,606 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $377,090 | -6.8% | 20,606 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $404,702 | +9.4% | 20,606 | +3.8% | 0.00% | 0.0% |
| Q2 2022 | $370,000 | -3.6% | 19,860 | +13.5% | 0.00% | 0.0% |
| Q1 2022 | $384,000 | -12.1% | 17,504 | +13.9% | 0.00% | 0.0% |
| Q4 2021 | $437,000 | +47.1% | 15,372 | +8.9% | 0.00% | 0.0% |
| Q3 2021 | $297,000 | +11.7% | 14,112 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $266,000 | +31.0% | 14,112 | +6.4% | 0.00% | – |
| Q1 2021 | $203,000 | +14.7% | 13,260 | +6.0% | 0.00% | – |
| Q4 2020 | $177,000 | – | 12,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |